Compass Pathways (NASDAQ:CMPS) reached a pivotal milestone on Wednesday, January 7, 2026, as the U.S. FDA accepted the company’s Investigational New Drug (IND) application for COMP360, its proprietary synthetic psilocybin treatment, for the treatment of Post-Traumatic Stress Disorder (PTSD).
Alcon (NYSE:ALC), the global leader in eye care, officially terminated its definitive merger agreement with STAAR Surgical Company (NASDAQ:STAA) on Tuesday, January 6, 2026.
The collapse of the deal, originally valued at $1.5 billion and later raised to approximately $1.6 billion, follows a decisive rejection by STAAR’s stockholders at a special meeting earlier that day.
Ionis Pharmaceuticals (NASDAQ:IONS) shares hovered near 52-week highs Wednesday after partner GSK (NYSE:GSK) announced that its experimental drug, bepirovirsen, successfully met the primary endpoints in two pivotal Phase 3 trials, B-Well 1 and B-Well 2.
Ascentage Pharma (NASDAQ:AAPG) shares were in focus on Tuesday, January 6, 2026, following the announcement that the U.S. FDA has cleared its Investigational New Drug (IND) application for APG-3288.
HUTCHMED (China) Limited (NASDAQ:HCM) shares climbed in after-hours trading Wednesday after the company announced that its novel Syk inhibitor, sovleplenib, met the primary endpoint in the Phase III registration portion of the ESLIM-02 trial.
Marvell Technology said on Tuesday it will buy networking equipment provider XConn Technologies in a deal worth about $540 million, as the chipmaker doubles down on data center hardware amid a race to expand artificial intelligence infrastructure.
Johnson & Johnson (NYSE:JNJ) announced on Tuesday, January 6, 2026, that its Phase 2b JASMINE study of nipocalimab in adults with moderate-to-severe systemic lupus erythematosus (SLE) met its primary and key secondary endpoints.
Zai Lab Limited (NASDAQ:ZLAB) announced on January 6, 2026, that China’s National Medical Products Administration (NMPA) has approved the supplemental New Drug Application (sNDA) for AUGTYRO™ (repotrectinib).
This approval targets adult patients with advanced or metastatic solid tumors harboring a neurotrophic tyrosine receptor kinase (NTRK) gene fusion.
Abpro Holdings (NASDAQ:ABP) and South Korean biopharma giant Celltrion announced on January 6, 2026, that the U.S. FDA has cleared the Investigational New Drug (IND) application for ABP-102 (CT-P72).
This clearance transitions Abpro’s lead oncology program into the clinic, targeting a wide array of HER2-positive solid tumors, including breast, gastric, colorectal, and pancreatic cancers.
Alumis (NASDAQ:ALMS) surged as much as 82% in early trading Tuesday after its experimental oral drug, envudeucitinib, outperformed both a placebo and Amgen’s blockbuster Otezla in two Phase 3 trials for moderate-to-severe plaque psoriasis.
Genprex (NASDAQ:GNPX) announced landmark preliminary preclinical data on January 6, 2026, for its diabetes gene therapy candidate, GPX-002.
Cognition Therapeutics (NASDAQ:CGTX) announced on January 6, 2026, the publication of peer-reviewed results from its Phase 2 SHIMMER study in the journal Alzheimer's & Dementia.
